Sign up Australia
Proactive Investors - Run By Investors For Investors

Regeneus granted key cancer treatment patent in Japan

The patent provides commercial rights in Japan through to 2033.
healthcare concept
The company is also pursuing corresponding patents for grant in the U.S. and Europe

Regeneus Ltd (ASX:RGS) has been granted a key patent in Japan covering the use of cancer vaccine technology for treatment of a range of cancers in humans and animals.

The Japanese Patent Office has issued a decision to allow the patent which will provide commercial rights for ACTIVATE in Japan through to 2033.

This technology uses a patient’s own cancer cells combined with an immune-stimulant designed to re-educate the immune system to target cancer cells in existing and new tumours.

Japanese Patent Application No. 2015-549902 is titled ‘Vaccines for the treatment or prevention of cancer and compositions for enhancing vaccine efficacy’.

Corresponding patent granted in Australia

A corresponding patent has been granted in Australia and Regeneus is pursuing corresponding patents for grant in other key territories including the U.S. and Europe.

The patent supports the company’s RGSH4K clinical programs for humans and Kvax clinical programs for animal health.

Phase I safety study for humans

RGSH4K is being tested in a phase I safety study in humans on a wide range of tumours being conducted through the Northern Cancer Institute at St Leonards in Sydney.

Patients have been treated in all three dose levels without any safety concerns.

This ACTIVATE Trial is expected to complete recruitment and report on the study results in the first half of 2018.

Study for canine osteosarcoma treatment

Kvax has been the subject of a successful U.S. study for the treatment of canine osteosarcoma.

Results showed that Kvax administered after limb amputation is safe and well tolerated.

It appears to confer increased progression free interval and improved survival compared to historically treated dogs with osteosarcoma treated with limb amputation only.

Kvax is also the subject of a study for the treatment of canine lymphosarcoma in combination with chemotherapy.

This is being conducted at the Small Animal Specialist Hospital at North Ryde in Sydney.

The technology was developed by researchers at the Bill Walsh Translational Cancer Research Laboratory at St Leonards.

This is the research arm of the Medical Oncology Department at Royal North Shore Hospital and is part of the Kolling Institute of Medical Research.

Animal survival extended significantly

In a pre-clinical brain tumour model conducted by researchers, vaccination led to remission rates of up to 60% and significantly extended survival in all vaccinated animals.

Re-challenging animals in remission demonstrated 100% tumour rejection indicating acquired immunity.

Regeneus is a clinical-stage regenerative medicine company using patented and scalable stem cell and immuno-oncology technologies to develop a portfolio of novel cell-based therapies.

The company has more than 70 patents or patent applications across multiple patent families relating to its regenerative medicine products.

READ: Regeneus shares rise as results show Sygenus gel successfully fights acne

Last week Regeneus was issued a notice of allowance by the United States Patent Office for a patent related to Sygenus for the treatment of acne.

The patent covers the composition, manufacture and use of the secretion stem cell technology platform, known as Sygenus.

View full RGS profile View Profile

Regeneus Ltd Timeline

Related Articles

April 01 2018
The company is in the process of raising £5mln, with a possible further £1mln through a share issue at 52.5p
cancer cells in blood
July 17 2018
It’s been a tricky year for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive
leg bones
March 31 2018
"We are now in the position of really trying to kick on in 2018"

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use